Research

News about the C9ORF72 gene, National ALS Registry and Cytokinetics' experimental drug was reported at the 2012 American Academy of Neurology meeting

Posted on Fri, 2012-04-27 10:49, By: Amy Labbe
Among the reports given at the 2012 annual meeting of the American Academy of Neurology, being held April 21-28 in New Orleans, was information about research into amyotrophic lateral sclerosis (ALS).
Read more...

ALS research news items on findings related to SOD1 in noninherited ALS, toxic SOD1 in ALS-affected tissue, and NIPA1 repeat expansions in ALS

Posted on Friday, April 13, 2012 - 06:00, By: Amy Labbe
SOD1 causes toxicity in some familial and some sporadic ALS In some people with bulbar-onset sporadic ALS, changes to the SOD1 protein cause the same toxicity as is generated by mutated SOD1 protein in the familial (inherited) form of the disease, a team of researchers has reported.
Read more...
Posted on Monday, April 9, 2012 - 09:41, By: Amy Labbe
Preventing, halting or reversing motor neuron damage is a primary goal of ALS research. But new ways of thinking about the disease are guiding scientists down different roads to that destination. MDA has awarded six new grants totaling $2 million to ALS researchers investigating some of these new...
Read more...

Transplantation of stem cells into the spinal cords of 12 people with ALS has proven safe and well-tolerated, with no long-term complications

Posted on Wednesday, April 4, 2012 - 06:00, By: Amy Labbe
Neuralstem's spinal cord stem cells, and the surgical technique used to transplant them, proved to be safe and well-tolerated in a phase 1 clinical trial in 12 people with amyotrophic lateral sclerosis (ALS). Although the trial wasn't designed to show efficacy, one participant showed signs of...
Read more...

A webinar hosted by ALS TDI reviews the biotech's development of TDI 132 (Gilenya), a drug that modulates the immune system      

Posted on Friday, March 23, 2012 - 12:51, By: Amy Labbe
An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.
Read more...

As progress continues in drug discovery and development at the ALS Therapy Development Institute, MDA's Augie's Quest provides $2 million more in support

Posted on Monday, March 5, 2012 - 06:00, By: Amy Labbe
MDA has extended its strategic research partnership with the ALS Therapy Development Institute (ALS TDI) through 2012 and awarded a $2 million grant to support the nonprofit biotech's continued efforts to develop treatments for ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
Read more...

ALS research update on findings related to abnormal functioning of mitochondria, cellular energy production and metabolism

Posted on Friday, February 24, 2012 - 15:01, By: Amy Labbe
Below are highlights of two recent studies in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
Read more...

The MDA-supported ALS Therapy Development Institute plans to launch a phase 2 clinical trial of TDI 132, a compound that modulates the immune system

Posted on Tuesday, February 14, 2012 - 11:30, By: Amy Labbe
A phase 2 clinical trial is set to begin of TDI 132, a compound that modulates the immune system, the ALS Therapy Development Institute (ALS TDI) announced today. TDI 132, also known as fingolimod (brand name Gilenya), already is approved by the U.S. Food and Drug Administration (FDA) for the...
Read more...

myMuscleTeam

Feedback Form
Feedback Analytics